PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
Press Release: Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease
Sanofi and Teva announce positive phase 2b results for duvakitug in ulcerative colitis and Crohn's disease, showing promising potential in IBD. Phase 3 development planned -
-
-
-
PRESS RELEASE
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
FDA designates tolebrutinib as Breakthrough Therapy for non-relapsing SPMS based on positive HERCULES study results. Sanofi awaits regulatory review for this innovative medicine -
-
PRESS RELEASE
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Sanofi's two combination vaccine candidates targeting influenza and COVID-19 granted Fast Track designation in the US. Candidates combine licensed vaccines to assess safety and immunogenicity in older adults
